These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

76 related articles for article (PubMed ID: 5509391)

  • 41. Losartan for hypertension.
    Med Lett Drugs Ther; 1995 Jun; 37(951):57-8. PubMed ID: 7783693
    [No Abstract]   [Full Text] [Related]  

  • 42. [Stroke prevention. Is there an added value to RAS inhibition?].
    MMW Fortschr Med; 2000 Feb; 142(6):62-3. PubMed ID: 10832360
    [No Abstract]   [Full Text] [Related]  

  • 43. [Controlled long-term study in senile hypertension].
    Bergener M; Mittelstaedt A
    Arzneimittelforschung; 1970 Oct; 20(10):1542-5. PubMed ID: 5536421
    [No Abstract]   [Full Text] [Related]  

  • 44. [Long-term antihypertensive therapy with moxonidine (cynt) in patients with insulin-independent diabetes mellitus].
    Lazebnik LB; Malichenko SB; Serebrov AN
    Ter Arkh; 1997; 69(6):59-64. PubMed ID: 9297279
    [No Abstract]   [Full Text] [Related]  

  • 45. Anti-hypertensive therapy by losartan. How effective is AT1 receptor blockade?
    Brunner HR
    J Hum Hypertens; 1995 Nov; 9(11):859-60. PubMed ID: 8583462
    [No Abstract]   [Full Text] [Related]  

  • 46. Safety and efficacy of moxonidine in mild to moderate hypertension.
    Jain S; Malhotra P; Kumari S; Varma S
    J Assoc Physicians India; 2001 Aug; 49():829-30. PubMed ID: 11837474
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The angiotensin II receptor antagonist losartan: a new advance in the treatment of hypertension.
    Lacourcière Y
    Can J Cardiol; 1995 Aug; 11 Suppl F():45F-48F. PubMed ID: 7664218
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Efficacy and safety of losartan.
    Goldberg A; Sweet C
    Can J Cardiol; 1995 Aug; 11 Suppl F():27F-32F. PubMed ID: 7664215
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Effect of prolonged treatment with 2-(2,6-dichlorophenylamine)-2-imidazoline HCl on renal hemodynamics in arterial hypertension].
    Ludwig H
    Arzneimittelforschung; 1968 May; 18(5):600-4. PubMed ID: 5755891
    [No Abstract]   [Full Text] [Related]  

  • 50. [Angiotensin-2 receptor blockade--new therapeutic approach to treatment of hypertension].
    Zimlichman R
    Harefuah; 1996 Jul; 131(1-2):43-5. PubMed ID: 8854479
    [No Abstract]   [Full Text] [Related]  

  • 51. [Effect of moxonidine monotherapy and in combination with melatonin on hemodynamic parameters in patients with arterial hypertension].
    Zaslavskaia RM; Komarov FI; Shakirova AN; Teĭblium MM; Akhmetov KZh
    Klin Med (Mosk); 2000; 78(4):41-4. PubMed ID: 10833890
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Blind trial with 2-(2,6-dichlorophenylamino)-2-imidazoline hydrochloride (ST 155) in essential hypertension. Effects on arterial blood pressures at rest and during exercise and on physical work capacity.
    Koch G
    Arzneimittelforschung; 1970 Dec; 20(12):1857-9. PubMed ID: 5537080
    [No Abstract]   [Full Text] [Related]  

  • 53. Angiotensin II antagonism: a new avenue of hypertension management.
    Gavras H
    Blood Press Suppl; 1997; 1():42-6. PubMed ID: 9285108
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Moxonidine improves glycaemic control in mildly hypertensive, overweight type 2 diabetic patients.
    Cardiovasc J Afr; 2007; 18(4):271. PubMed ID: 17940677
    [No Abstract]   [Full Text] [Related]  

  • 55. Losartan and low-dose hydrochlorothiazide in patients with essential hypertension. A double-blind, placebo-controlled trial of concomitant administration compared with individual components.
    MacKay JH; Arcuri KE; Goldberg AI; Snapinn SM; Sweet CS
    Arch Intern Med; 1996 Feb; 156(3):278-85. PubMed ID: 8572837
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [The first clinical experience in Italy with angiotensin II receptor antagonists: results of a multicenter study on the efficacy and tolerance in arterial hypertension].
    Trimarco B
    Cardiologia; 1995 Dec; 40(12 Suppl 1):193-5. PubMed ID: 8998714
    [No Abstract]   [Full Text] [Related]  

  • 57. Solvay addresses unmet needs in the management of hypertensive patients with cardiometabolic and lipid disorders.
    Cardiovasc J Afr; 2009; 20(1):73-4. PubMed ID: 19287821
    [No Abstract]   [Full Text] [Related]  

  • 58. [Angiotensin II receptor antagonists. Clinical relevance].
    Scholze J
    Internist (Berl); 1996 Jun; 37(6):636-42. PubMed ID: 8767999
    [No Abstract]   [Full Text] [Related]  

  • 59. [Experimental and clinical experiences with allercur].
    SCHWAB W
    Arch Ohren Nasen Kehlkopfheilkd; 1953; 162(5):458-62. PubMed ID: 13092898
    [No Abstract]   [Full Text] [Related]  

  • 60. [Report on experiences with the drug Haemiton].
    Müller D
    Dtsch Gesundheitsw; 1970 Aug; 25(32):1517. PubMed ID: 5509391
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.